Evanka Madan

Evanka Madan

Auto-generated profile, based on publicly available information

Evanka Madan

Department of Biotechnology and Research, Sir Ganga Ram Hospital, New Delhi, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KJKriti Jain
Kriti Jain
AGAnika Goel
Anika Goel
DMDeepa Mehra
Deepa Mehra
DRDeepak Kumar Rathore
Deepak Kumar Rathore
ABAkshay Binayke
Akshay Binayke
NGNirmal Kumar Ganguly
Nirmal Kumar Ganguly
Background: This study investigates the predictive potential of circulating cytokines for response and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor (ICI) therapy.Materials and methods: A cohort of 64 patients with advanced NSCLC receiving ICI therapy were included. Baseline serum samples were collected prior to ICI initiation and profiled using a multiplex cytokine panel. Logistic regression, Cox regression, and Kaplan-Meier survival analysis were employed to assess associations between cytokine levels, therapeutic response, progression-free survival (PFS), and overall survival (OS). Gene expression levels of key cytokines were validated in peripheral blood mononuclear cells (PBMCs) of 17 patients (Responders = 7, Non-Responders = 10) and 3 Healthy Controls using quantitative real-time PCR.Results: Elevated baseline levels of IL-2, IL-23, and sPD-L1 were significantly associated with clinical response to ICI therapy. Among these, sPD-L1 emerged as an independent predictor of response (AUC = 0.87). Multivariate Cox regression showed IL-2 (HR = 0.67), sPD-L1 (HR = 0.15), and IL-23 (HR = 1.18) were significantly associated with PFS and also predictive of OS. Notably, combined profiling of IL-2 and sPD-L1 enhanced predictive power (AUC = 0.95 for both PFS and OS). RT-PCR analysis of PBMCs corroborated these findings, confirming upregulation of IL-2 in responders and elevated IL-23 expression in non-responders.Conclusion: Baseline cytokine profiling particularly of IL-2, sPD-L1, and IL-23 provides important prognostic and predictive information in advanced NSCLC patients undergoing ICI therapy. These biomarkers may facilitate more personalized approaches to immunotherapy and guide clinical decision-making.

18 May 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
IEIfeoma Ezenyi
Ifeoma Ezenyi
EMEvanka Madan
Evanka Madan
JSJhalak Singhal
Jhalak Singhal
RJRavi Jain
Ravi Jain
ACAmrita Chakrabarti
Amrita Chakrabarti
SSShailja Singh
Shailja Singh
Available anti-leishmanial drugs are associated with toxic side effects, necessitating the search for safe and effective alternatives. This study is focused on identifying traditional medicinal plant natural products for anti-leishmanial potential and possible mechanism of action. Compounds S and T. cordifolia residual fraction (TC-5) presented the best anti-leishmanial activity (IC50: 0.446 and 1.028 mg/ml) against promastigotes at 48 h and less cytotoxicity to THP-1 macrophages. These test agents elicited increased expression of pro-inflammatory cytokines; TNF alpha and IL-12. In infected untreated macrophages, NO release was suppressed but was significantly (p < 0.05) increased in infected cells treated with compound S. Importantly, Compound S was found to interact with LdTopoII(dimer) in silico, resulting in a likely reduced ability of nucleic acid (dsDNA)-remodelling and, as a result, parasite proliferation in vitro. Thereby, Compound S possesses anti-leishmanial activity and this effect occurs via a Th1-mediated pro-inflammatory response. An increase in NO release and its inhibitory effect on LdTopoII may also contribute to the anti-leishmanial effect of compound S. These results show the potential of this compound as a potential starting point for the discovery of novel anti-leishmanial leads.Communicated by Ramaswamy H. Sarma

14 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KJKriti Jain
Kriti Jain
AGAnika Goel
Anika Goel
DMDeepa Mehra
Deepa Mehra
DRDeepak Kumar Rathore
Deepak Kumar Rathore
ABAkshay Anil Binayke
Akshay Anil Binayke
NGNirmal Kumar Ganguly
Nirmal Kumar Ganguly
Background: This study investigates the predictive potential of circulating cytokines for response and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor (ICI) therapy. Materials and Methods: A cohort of 64 patients with advanced NSCLC receiving ICI therapy were included. Baseline serum samples were collected prior to ICI initiation and profiled using a multiplex cytokine panel. Logistic regression, Cox regression, and Kaplan-Meier survival analysis were employed to assess associations between cytokine levels, therapeutic response, progression-free survival (PFS), and overall survival (OS). Gene expression levels of key cytokines were validated in peripheral blood mononuclear cells (PBMCs) using quantitative real-time PCR. Results: Elevated baseline levels of IL-2, IL-23, and sPD-L1 were significantly associated with clinical response to ICI therapy. Among these, sPD-L1 emerged as an independent predictor of response (AUC = 0.87). Multivariate Cox regression showed IL-2 (HR = 0.67), sPD-L1 (HR = 0.15), and IL-23 (HR = 1.18) were significantly associated with PFS and also predictive of OS. Notably, combined profiling of IL-2 and sPD-L1 enhanced predictive power (AUC = 0.95 for both PFS and OS). RT-PCR analysis of PBMCs corroborated these findings, confirming upregulation of IL-2 in responders and elevated IL-23 expression in non-responders. Conclusion: Baseline cytokine profiling particularly of IL-2, sPD-L1, and IL-23 provides important prognostic and predictive information in advanced NSCLC patients undergoing ICI therapy. These biomarkers may facilitate more personalized approaches to immunotherapy and guide clinical decision-making.

30 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSoumyadeep Mukherjee
Soumyadeep Mukherjee
ASArushi Sharma
Arushi Sharma
PUPrince Upadhyay
Prince Upadhyay
EMEvanka Madan
Evanka Madan
SPSoumya Pati
Soumya Pati
SSShailja Singh
Shailja Singh
Cysteine proteome essentially regulates cellular adaptability during stress. Proteomic cysteines are reversibly modified to avoid loss through oxidation. Reversible cysteine-modifications beneficially preserve cellular stress-response mechanisms by regulating the transient activation of substrate proteins. Cysteine acylation (or s-acylation) is one such extensively documented reversible protein modification. Inflammation-responsive changes in s-acylation facilitate the plasticity of immune-partitioned brains by dynamically determining the ‘utilization’ of stress-buffering (substrate) cysteine-proteins in microglia, the primary immune-reactive brain cells. However, the inflammation-responsiveness of cysteine-acylation in microglia is not elaborately measured at a large-scale. Therefore, we observed the differential (quantitative) s-acylation of proteins in cultured human (HMC3) microglia by implementing comparative MLCC-based chemoproteomic workflows. Parallelly, we characterized the molecular consequences of HMC3 cell treatment with 2-bromopalmitate, a general s-acylation inhibitor, by performing immunocytochemistry and proteomic experiments. We also identified the s-acylation-dependent microglial inflammatory responses through live spatiotemporal tracking and confocal microscopy, following treatment of microglia with PAMPs (LPS or IFNy). Finally, from our proteomic studies of postmortem human brain tissues, we confirmed major protein-causals of schizophrenia, a redox-related brain disorder, to undergo inflammation-responsive s-acylation. This report provides a first comprehensive library of cysteine-proteins differentially processed through inflammation-responsive acylation in microglia. It also outlines the inflammation-responsive s-acylation of key NRF2-antioxidants, including peroxiredoxins (especially PRDX2) and glutathione synthetase (GSS), as a biochemical signature of early-stage inflammation and oxidative-stress in microglia. More importantly, the innovative proteo-informatic workflows designed for this research work can be reliably repurposed to identify bifunctional theragnostic protein markers of many complex disorders and diseases.

6 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EMEvanka Madan
Evanka Madan
VJVaibhav Jain
Vaibhav Jain
Vijay Pal SinghVijay Pal Singh
Vijay Pal Singh
Reduced mitochondrial function is one of the various cellular pathologies in cardio-metabolic syndrome. Elevated asymmetric dimethyl arginine (ADMA) levels is known to induce hypoxia driven mitochondrial dysfunction in the lungs, despite normoxic conditions. This alteration is known to be caused by interleukin-4 (IL-4). In addition to asthma, IL-4 and ADMA are also known to be elevated in metabolic syndrome (MetS), but the existence of hypoxic response in arterial tissue remains elusive. Since, MetS and asthma are correlated; we explored whether hypoxia exists in vascular tissue and is associated with IL-4 and ADMA levels. To induce MetS, C57BL/6 mice were fed chow, high-fat or high-fructose diets for six months. Interestingly, MetS was associated with the induction of the hypoxic response in aortic tissue. Further, IL-4 and ADMA, which induce aberrant hypoxic response despite normoxia in the lungs, were elevated in the aorta of mice with MetS. Additionally, significant reductions in the levels of mitochondrial biogenesis factors (TFAM, PGC1α) and respiratory chain complexes (Complex I and Complex IV) activities were observed in MetS mice. Mitochondrial dysfunction in the aorta of mice with MetS perturbed mitochondrial inner membrane integrity and was associated with the leakage of cytochrome c in the cytosol. These results collectively suggest that elevated levels of IL-4 and ADMA in the aorta of mice with MetS correlates with induced vascular mitochondrial dysfunction and hypoxic response.

9 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EMEvanka Madan
Evanka Madan
RBRuby Bansal
Ruby Bansal
JSJhalak Singhal
Jhalak Singhal
MSMonica Saini
Monica Saini
SSSadat Shafi
Sadat Shafi
SSShailja Singh
Shailja Singh
Background: Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator regulating apoptosis, proliferation, and immune responses. While S1Ps presence in Leishmania donovani phagolysosomes has been reported, the role of sphingosine kinases, especially SphK1, in parasite survival and host immune modulation remains underexplored. This study investigates the molecular and functional role of L. donovani SphK1 ( Ld SphK1) and evaluates the antileishmanial potential of PF-543, a specific SphK1 inhibitor. Methods: Ld SphK1 and human SphK1 ( rh SphK1) were cloned, expressed in E. coli , purified, and analyzed by SDS-PAGE. Enzymatic activity and inhibition by PF543 were assessed using NBD-S1P-based fluorometric assays. Protein-ligand interactions were analyzed using Microscale Thermophoresis (MST). Leishmania promastigotes overexpressing Ld SphK1 were studied via confocal microscopy, and their viability and infectivity were assessed in vitro . THP-1 macrophages infected with L. donovani were treated with PF543 alone or with Amphotericin B and analyzed by MTT assay, RT-PCR, Giemsa staining, ELISA and immunoblotting. In vivo efficacy was tested in L. donovani -infected Swiss mice. Results: rLd SphK1 (∼102 kDa) and rh SphK1 (∼50 kDa) were enzymatically active and significantly inhibited by PF-543. MST confirmed high-affinity binding of PF-543 (KD ∼29 microMolar). In L. donovani SphK1 overexpressor (Ld SphKa) promastigotes, PF543 inhibited SphK1 activity and reduced parasite infectivity, more than in wildtype L. donovani promastigotes. Notably, PF543 treatment reduced parasite infectivity in vitro , lowered amastigote load by ∼40%, and promoted a pro-inflammatory cytokine shift (↑IL-12, ↑TNF-α, ↓IL-10). Inhibition of ceramide synthesis and S1P supplementation revealed that S1P rescues ceramide-induced parasite death, implicating SphK1 in parasite survival. PF543 and Amphotericin B demonstrated synergistic anti-parasitic effects both in vitro and in vivo , with >90% reduction in parasite burden in mice. Conclusion: PF543 is a potent inhibitor of SphK1, impairing parasite survival and modulating host immune responses. When combined with Amphotericin B, it offers a synergistic therapeutic strategy against visceral leishmaniasis, warranting further clinical exploration. Author Summary: Leishmaniasis, a neglected tropical disease, has limited available treatments and is becoming more resistant to medications. In this study, we explored the therapeutic potential of PF-543, a potent sphingosine kinase 1 (SphK1) inhibitor (demonstrated anticancer effects in various preclinical models) against Leishmania donovani . We successfully cloned and purified both Leishmania and human SphK1 proteins and confirmed PF-543 binding through biochemical and biophysical assays. Overexpression of Ld SphK1 in parasites enhanced their survival and infectivity. In vitro, PF-543 treatment of infected macrophages decreased amastigote burden, shifted cytokine profiles towards a pro-inflammatory state, and enhanced host cell apoptosis. Notably, PF-543 acted synergistically with Amphotericin B, the current clinical drug, both in vitro and in vivo in Swiss mice, drastically lowering parasite burden. This study highlights the possibility of combination therapy and finds PF-543 to be a promising irresistible host-targeted antileishmanial drug. Graphical